Eosinophilic phenotype was associated with better early clinical remission in elderly patients but not middle-aged patients with acute exacerbations of COPD.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
11
11
2020
accepted:
24
05
2021
pubmed:
29
5
2021
medline:
18
8
2021
entrez:
28
5
2021
Statut:
ppublish
Résumé
There is limited evidence of the relationship between peripheral blood eosinophils and clinical remission of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) at different ages, especially in elderly patients, which was the objective of the present study. This retrospective study stratified patients by age (elderly patients >65 years old or middle-aged patients between 45 and 65 years old) and analysed the relationship between blood eosinophils (≥2% or <2%) and AECOPD clinical remission at observing time points of 7, 14, 21 and 28 days of hospitalisation. Student's t tests, Mann-Whitney U tests, Chi-squared or Fisher's exact tests were conditionally used to compare difference between groups. The unadjusted or adjusted Cox proportional hazards model was used to analyse the association between blood eosinophilic levels and cumulative clinical remission. Of 703 AECOPD cases analysed, 616 were elderly people (>65 years), 312 of whom had eosinophilic exacerbations. There were statistically significant differences in leucocytes, eosinophils, neutrophils, lymphocytes, monocytes, high-sensitivity C-reactive protein levels (hs-CRP), and hospital costs between groups (P < .05, respectively). According to the chi-square analysis, eosinophilic exacerbation had a higher clinical remission rate at 7, 14 and 21 days (all P < .05), but not 28 days (P > .05). Among analysis through adjusted Cox proportional hazards model, eosinophilic exacerbation was significantly associated with a higher cumulative remission rate in elderly patients at 7, 14, 21 days (all P < .05), but not 28 days (P > .05). No significant association was observed in meddle-aged patients at any time points (all P > .05). Eosinophilic exacerbation was associated with better early clinical remission of AECOPD patients during hospitalisation. As stratified by ages, similar results were observed in elderly patients but not middle-aged patients. Blood eosinophils at different ages may be valuable in personalised management for AECOPD.
Sections du résumé
BACKGROUND
BACKGROUND
There is limited evidence of the relationship between peripheral blood eosinophils and clinical remission of acute exacerbations of chronic obstructive pulmonary disease (AECOPD) at different ages, especially in elderly patients, which was the objective of the present study.
METHODS
METHODS
This retrospective study stratified patients by age (elderly patients >65 years old or middle-aged patients between 45 and 65 years old) and analysed the relationship between blood eosinophils (≥2% or <2%) and AECOPD clinical remission at observing time points of 7, 14, 21 and 28 days of hospitalisation. Student's t tests, Mann-Whitney U tests, Chi-squared or Fisher's exact tests were conditionally used to compare difference between groups. The unadjusted or adjusted Cox proportional hazards model was used to analyse the association between blood eosinophilic levels and cumulative clinical remission.
RESULTS
RESULTS
Of 703 AECOPD cases analysed, 616 were elderly people (>65 years), 312 of whom had eosinophilic exacerbations. There were statistically significant differences in leucocytes, eosinophils, neutrophils, lymphocytes, monocytes, high-sensitivity C-reactive protein levels (hs-CRP), and hospital costs between groups (P < .05, respectively). According to the chi-square analysis, eosinophilic exacerbation had a higher clinical remission rate at 7, 14 and 21 days (all P < .05), but not 28 days (P > .05). Among analysis through adjusted Cox proportional hazards model, eosinophilic exacerbation was significantly associated with a higher cumulative remission rate in elderly patients at 7, 14, 21 days (all P < .05), but not 28 days (P > .05). No significant association was observed in meddle-aged patients at any time points (all P > .05).
CONCLUSION
CONCLUSIONS
Eosinophilic exacerbation was associated with better early clinical remission of AECOPD patients during hospitalisation. As stratified by ages, similar results were observed in elderly patients but not middle-aged patients. Blood eosinophils at different ages may be valuable in personalised management for AECOPD.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14415Subventions
Organisme : 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
ID : ZYGD18006
Organisme : 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University
ID : ZYJC18012
Organisme : Science and Technology Project of the Health Planning Committee of Sichuan
ID : 20PJ042
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med. 2019;381;1257-1266.
Soriano JB, Kendrick PJ, Paulson KR, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8:585-596.
Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018;391:1706-1717.
Chan KY, Li X, Chen W, et al. Prevalence of chronic obstructive pulmonary disease (COPD) in China in 1990 and 2010. J Glob Health. 2017;7:
Zhu B, Wang Y, Ming J, et al. Disease burden of COPD in China: a systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:1353-1364.
Lou P, Zhu Y, Chen P, et al. Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study. BMC Pulm Med. 2012;12:53.
GOLD-Workshop. 2020 GOLD Reports. 2020 Global Strategy for Prevention, Diagnosis and Management of COPD; 2020. https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf. Accessed November 08, 2020.
Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:580-584.
Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003;124:459-467.
Escarrabill J. Discharge planning and home care for end-stage COPD patients. Eur Respir J. 2009;34:507-512.
Fermont JM, Bolton CE, Fisk M, et al. Risk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational study. PLoS One. 2020;15:e0228940.
Whittaker Brown SA, Braman S. Recent advances in the management of acute exacerbations of chronic obstructive pulmonary disease. Med Clin North Am. 2020;104:615-630.
Prins HJ, Duijkers R, Lutter R, et al. Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD. Respir Med. 2017;131:118-124.
Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3:435-442.
Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. the copenhagen general population study. Am J Respir Crit Care Med. 2016; 193:965-974.
Ho J, He W, Chan MTV, et al. Eosinophilia and clinical outcome of chronic obstructive pulmonary disease: a meta-analysis. Sci Rep. 2017;7:13451.
Bafadhel M, Greening NJ, Harvey-Dunstan TC, et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest. 2016;150:320-328.
Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6:117-126.
Zhang Y, Liang LR, Zhang S, et al. Blood eosinophilia and its stability in hospitalized COPD exacerbations are associated with lower risk of all-cause mortality. Int J Chron Obstruct Pulmon Dis. 2020;15:1123-1134.
Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44:1697-1700.
Cai BQ, Cai SX, Chen RC, et al. Expert consensus on acute exacerbation of chronic obstructive pulmonary disease in the People's Republic of China. Int J Chron Obstruct Pulmon Dis. 2014;9:381-395.
. Chinese Chronic Obstructive Pulmonary Diseases Study Group, Chinese Society of Respiratory Diseases. Guideline for diagnosis and management of chronic obstructive pulmonary diseases in China (Revised 2013). Chin J Tubere Respir Dis. 2013;36:255-264.
Chinese Thoracic Society. The guideline of community-acquired pneumonia diagnosis and treatment. Chin J Tuberc Resp Dis. 2006;29:651-655.
Nair K, Ghushchyan V, Van Den Bos J, et al. Burden of illness for an employed population with chronic obstructive pulmonary disease. Popul Health Manage. 2012;15:267-275.
Crisafulli E, Ielpo A, Barbeta E, et al. Clinical variables predicting the risk of a hospital stay for longer than 7 days in patients with severe acute exacerbations of chronic obstructive pulmonary disease: a prospective study. Respir Res. 2018;19:261.
"Guidelines for Clinical Use of Antibacterials" Workshop. Guidelines for Clinical Use of Antibacterials (2015 edition). http://www.gov.cn/foot/site1/20150827/9021440664034848.pdf. Accessed April 27, 2021.
"Guidelines for Clinical Use of Antibacterials" Workshop. Guidelines for Clinical Use of Antibacterials (2004 edition); 2004. http://www.nhc.gov.cn/wjw/zcjd/201304/2da63e01325e4df8a235590112321403.shtml. Accessed April 27, 2021.
Hu YH, Liang ZY, Xu LM, et al. Comparison of the clinical characteristics and comprehensive assessments of the 2011 and 2017 GOLD classifications for patients with COPD in China. Int J Chron Obstruct Pulmon Dis. 2018;13:3011-3019.
Celli BR, MacNee W, Agusti A, et al. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-946.
Aydindogan E, Penque D, Zoidakis J. Systematic review on recent potential biomarkers of chronic obstructive pulmonary disease. Expert Rev Mol Diagn. 2019;19:37-45.
Wu HX, Zhuo KQ, Cheng DY. Prevalence and baseline clinical characteristics of eosinophilic chronic obstructive pulmonary disease: a meta-analysis and systematic review. Front Med. 2019;6:282.
Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186:48-55.
Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med. 2020;41:421-438.
Greulich T, Tüffers J, Mager S, et al. High eosinophil blood counts are associated with a shorter length of hospital stay in exacerbated COPD patients - a retrospective analysis. Respir Res. 2020;21:106.
Santamaria AY, Romero MM, Romero RS, Herrera HM. Factors associated with a prolonged hospital length of stay in a population of patients with exacerbation of chronic obstructive pulmonary disease in a reference hospital in Northeastern Colombia. Rev Am Med Respir. 2019;19:321-328.
Oishi K, Matsunaga K, Shirai T, et al. Role of type2 inflammatory biomarkers in chronic obstructive pulmonary disease. J Clin Med. 2020;9:2670.
Eltboli O, Bafadhel M, Hollins F, et al. COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils. BMC Pulm Med. 2014;14:112.
Wei B, Sheng LC. Changes in Th1/Th2-producing cytokines during acute exacerbation chronic obstructive pulmonary disease. J Int Med Res. 2018;46:3890-3902.
Wu C-W, Lan C-C, Hsieh P-C, et al. Role of peripheral eosinophilia in acute exacerbation of chronic obstructive pulmonary disease. World J Clin Cases. 2020;8:2727-2737.
Wu HX, Zhuo KQ, Cheng DY. Peripheral blood eosinophil as a biomarker in outcomes of acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2019;14:3003-3015.
Russell R, Beer S, Pavord ID, et al. The acute wheezy adult with airways disease in the emergency department: a retrospective case-note review of exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:971-977.
Chen WR, Zhang WQ. Comparison of drug economics of different drug treatment schemes COPD. China J Pharm Econom. 2017;12:5-7.
Lim S, Lam D-L, Muttalif AR, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. Asia Pac Fam Med. 2015;14:4.
Lahousse L, Ziere G, Verlinden VJA, et al. Risk of frailty in elderly with COPD: a population-based study. J Gerontol A Biol Sci Med Sci. 2016;71:689-695.
Incalzi RA, Scarlata S, Pennazza G, et al. Chronic obstructive pulmonary disease in the elderly. Eur J Intern Med. 2014;25:320-328.
Zhang Y, Liu X, Kong D, et al. Effects of ambient temperature on acute exacerbations of chronic obstructive pulmonary disease: results from a time-series analysis of 143318 hospitalizations. Int J Chron Obstruct Pulmon Dis. 2020;15:213-223.
Shen Y, Zhang X, Chen C, et al. The relationship between ambient temperature and acute respiratory and cardiovascular diseases in Shenyang. Environ Sci Pollut Res Int. 2021;28(16):20058-20071.
Anzueto A. Impact of exacerbations on COPD. Eur Respir Rev. 2010;19:113-118.